Table 1.
Patient Baseline Characteristics According to Human Immunodeficiency Virus Status
| Characteristic | HIV+ (n = 70) | HIV− (n = 45) | P value |
|---|---|---|---|
| Age, median (IQR) | 41 (23–64) | 42 (32–52) | .70 |
| Race/ethnicity, no. (%) | |||
| White | 31 (44) | 32 (71) | .01 |
| Black | 14 (20) | 3 (7) | |
| Hispanic | 19 (27) | 5 (11) | |
| Other | 6 (9) | 5 (11) | |
| Smoking status, no. (%) | |||
| Current smoker | 17 (24) | 5 (11) | .10 |
| Former smoker | 16 (23) | 15 (33) | |
| Never smoker | 37 (53) | 25 (56) | |
| CD4 Count, median cells/mm3 (IQR) | 677 (469–865) | N/A | |
| HIV RNA (copies/mL), no. (%) | |||
| <50 | 40 (57) | N/A | |
| 50–1000 | 18 (26) | ||
| ≥1000 | 12 (17) | N/A | |
| High-risk HPV type, no. (%) | |||
| 16,18, or both | 34 (49) | 21 (47) | .007 |
| Others | 28 (40) | 11 (24) | |
| Negative | 3 (4) | 0 (0) | |
| Unknown | 5 (7) | 13 (29) | |
| Anorectal cytology, no. (%) | |||
| LSIL or less | 49 (70) | 26 (58) | .001 |
| HSIL or ASC-H | 17 (24) | 5 (11) | |
| Unknown | 4 (6) | 14 (31) | |
| HPV vaccination, no. (%) | 15 (21) | 16 (36) | .20 |
| Number of biopsy-proven HSILs, no. (%) | |||
| Unifocal | 20 (29) | 29 (64) | <.001 |
| Multifocal | 50 (71) | 16 (36) | |
Abbreviations: ASC-H, atypical squamous cells, cannot rule out high-grade lesion; HIV, human immunodeficiency virus; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; IQR, intraquartile range; LSIL, low-grade squamous intraepithelial lesion.